Skip to content

U-100 unit conversion

Cistanche tubulosa calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

5U-100 units · 0.05 mL

50 mcg per unit · 5000 mcg/mL

How the calculator works, sources and review dates

Cistanche tubulosa math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 10 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-09. source-curated; clinician review pending.

Units chart for listed Cistanche tubulosa sizes

This card has no units chart until a milligram size is listed.

What is Cistanche tubulosa?

Other names in the library: desert ginseng, Cistanche. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: no listed milligram sizes in the vendor file. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Regulatory context

Regulatory context; not efficacy evidence

No matched clinical trial of this exact supplier preparation was verified.

Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Traditional use and ingredient marketing are not clinical efficacy evidence.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

Cistanche tubulosa extract: randomized mobility study (2021)

26 analyzed participants with mild or presymptomatic locomotive syndrome; 12-week blinded placebo-controlled study.

Reported findings. No positive effect established on the stated primary outcome.

Nonresponse. Gait measures improved in an older subgroup; muscle mass did not change.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Small sample and subgroup result. Exact extract standardization matters; neither generalized anabolic benefit nor commercial-product equivalence is established.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

Cistanche tubulosa extract: randomized mobility study (2021)

Placebo-controlled locomotor-function study; positive walking findings restricted to older subgroups.

Reported findings. Some walking findings were positive in older subgroups.

Nonresponse. Full-sample physical-function comparisons were null; muscle mass unchanged.

Harms. No adverse effects observed in the study; general safety not established.

Limits. Species/extract-specific study, not complete evidence for generic Cistanche supplements. Subgroup findings require cautious interpretation.

Preparation: C. tubulosa ethanol extract containing 5.41% acteoside and 17.48% echinacoside; commercial species/extract equivalence unverified. Route: oral

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

<i>Cistanche tubulosa</i>-<i>Ginkgo biloba</i> combination enhances memory via cortico-cerebellar reorganization: a randomized controlled trial.

117 healthy adults randomized double-blind for30days; MRI subset15.

Reported findings. Several memory outcomes favored the combination versus placebo.

Nonresponse. Portrait-memory between-group result nonsignificant, p0.065; meaningless-graphics recognition declined in both groups, less with combination.

Harms. No spontaneously reported adverse events during30days; limited surveillance does not establish comprehensive safety.

Limits. Cannot separate Cistanche contribution from Ginkgo or establish catalog extract equivalence. MRI correlations and subset15 do not establish a causal neural mechanism. Study2019-2020 with registration identifierChiCTR2400084102; prospective registration not established.

Preparation: Oral Nutrilite/Amway Cistanche tubulosa plus Ginkgo biloba standardized-extract combination; not catalog Cistanche alone. Route: Oral combined tablets; not isolated Cistanche or injectable peptide exposure.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

source limited. No matched clinical trial of this exact supplier preparation was verified.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. Regulatory context; not efficacy evidence · checked 2026-10-09
  2. Cistanche tubulosa extract: randomized mobility study (2021) · checked 2026-10-09

Questions people ask

Is Cistanche tubulosa FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of Cistanche tubulosa?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed Cistanche tubulosa vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.